EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500.Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung can- cer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500....
EGFR gene mutations, exon 19 deletions and exon 21 point mutations (L858R) are good predictors of response to EGFR-TKI treatment. The aim of this study was to assess the incidence of EGFR mutations in a large cohort of Europeans with advanced NSCLC and subsequently to evaluate their impact ...
EGFR-mutant ''oncogene-addicted'' cancers have been shown to be a distinct form of NSCLC, and can be targeted with erlotinib. In this study, researchers from the Spanish Lung Cancer Group evaluated the benefits of treatment for NSCLC, customized on the basis of EGFR mutations, in the largest...
Background The allele frequency of epidermal growth factor receptor (EGFR) mutations could be a potential molecular biomarker for the outcome of osimertinib therapy.Objective The purpose of our study was to assess the clinical relevance of the allele frequency of EGFR mutations in plasma-based ...
谢谢。[translate] aEGFR mutations may lead to constitutive activation of anti-apoptotic and proliferation signaling pathways. EGFR变化也许导致anti-apoptotic和扩散信号路的结构性活化作用。[translate]
本实验拟在肝癌组织中检测EGFR、EGFR mutations(EGFR mutations(del)和EGFR mutations(p))的表达及其与临床病理关系,为肝癌的分子靶向治疗提供理论依据和临床指导。 目的在肝癌组织中检测EGFR、EGFR mutations(EGFRmutations(del)和EGFR mutations(p))的表达及分析其与临床病理关系,为肝癌的分子靶向治疗提供理论依据和...
The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods invol...
www.nature.com/scientificreports OPEN received: 29 February 2016 accepted: 22 July 2016 Published: 16 August 2016 Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer Ying Jin1,2, Ming Chen2,3 & Xinmin Yu1 ...
But for NSCLC patients without EGFR mutations (known as EGFR wild-type) ― which is a much larger patient population ― the situation appears to be the direct opposite. Anew meta-analysis, published on April 9 in theJournal of the American Medical Association,suggests that conventional chemotherap...
EGFR‐tyrosine kinase inhibitors play an important role in the treatment of advanced non‐small cell lung cancer (NSCLC).EGFRmutations in advanced NSCLC occur in approximately 35% of Asian patients and 60% of patients with adenocarcinoma. However, the frequency and type ofEGFRmutations in early‐...